EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma

Ke Zhao iD, Hong-Tao Hu, Hai-Liang Li, Hong-Tao Cheng, Ya-Nan Zhao, Yuan Hang, Quan-Jun Yao

PLOS One · 2025

DOI: 10.1371/journal.pone.0323829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ke Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou City, Henan Pr…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Embolization, Therapeutic, Splenic Artery, Liver Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background To explore the safety and effectiveness of partial splenic embolization (PSE) in patients with hypersplenism and hepatocellular carcinoma (HCC) and to compare the efficacy of superselective and non-superselective embolization of splenic artery branches. Procedure We retrospectively analyzed 64 patients with HCC who underwent PSE between August 2020 and December 2022. The patients were categorized into two groups based on different treatment plans: Group A (n=33) underwent superselective embolization and Group B (n=31) underwent non-superselective embolization of the splenic artery branches. The safety and effectiveness of the two methods were evaluated along with changes in peripheral blood cells [mainly white blood cells (WBC) and red blood cells (RBC)] and platelet (PLT) counts at different time points after PSE. Postoperative adverse events were also compared between the two groups, Results The technical success rate was 100% for both procedures. The PLT and WBC counts of the two groups significantly increased one week after PSE (P0.05). The incidence of fever and pain in Group B was significantly higher than that in Group A (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularEmbolization, TherapeuticSplenic ArteryLiver NeoplasmsLiver CirrhosisHumansMaleFemaleMiddle AgedRetrospective StudiesAgedHypersplenismTreatment OutcomeAdult

Autor:innen und Institutionen

  • Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou City, Henan Province, China.

ORCID-Profile: Ke Zhao

Zitieren

APA

Zhao, K., Hu, H. T., Li, H. L., Cheng, H. T., Zhao, Y. N., Hang, Y., & Yao, Q. J. (2025). Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma. PLOS One. https://doi.org/10.1371/journal.pone.0323829

Vancouver

Zhao K, Hu HT, Li HL, Cheng HT, Zhao YN, Hang Y, et al. Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma. PLOS One. 2025. doi:10.1371/journal.pone.0323829

BibTeX
@article{Zhao2025,
  author = {Zhao, Ke and Hu, Hong-Tao and Li, Hai-Liang and Cheng, Hong-Tao and Zhao, Ya-Nan and Hang, Yuan and Yao, Quan-Jun},
  title = {Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0323829}
}
Kostenlos starten →